Megestrol acetate treatment influences tissue amino acid uptake and incorporation during cancer cachexia

e-SPEN Journal

Volumn 7, Issue 4, 2012, Pages

  Toledo, Míriam ^a   Marmonti, Enrica ^a   Massa, David ^a   Mola, Marina ^a   López Soriano, Francisco J ^a   Busquets, Sílvia ^a   Argilés, Josep M ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

BCAA; Cancer cachexia; Liver; Megestrol acetate; Skeletal muscle; Therapy

Indexed keywords

ALANINE DERIVATIVE; ALPHA AMINO 3H ISOBUTYRATE; LEUCINE; MEGESTROL ACETATE; UNCLASSIFIED DRUG;

AMINO ACID TRANSPORT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CACHEXIA; CONTROLLED STUDY; LIVER; MALE; MUSCLE ATROPHY; MUSCLE MASS; MUSCLE TISSUE; NONHUMAN; OXIDATION; RAT; SKELETAL MUSCLE; THERAPY EFFECT; TUMOR XENOGRAFT;

EID: 84864740826     PISSN: None     EISSN: 22128263     Source Type: Journal    
DOI: 10.1016/j.clnme.2012.04.001     Document Type: Article

References (24)

1. Evans W.J., Morley J.E., Argiles J., Bales C., Baracos V., Guttridge D., et al. Cachexia: a new definition. Clin Nutr 2008, 27(6):793-799.
2. Argiles J.M., Alvarez B., Lopez-Soriano F.J. The metabolic basis of cancer cachexia. Med Res Rev 1997, 17(5):477-498.
3. Argiles J.M., Lopez-Soriano F.J. Why do cancer cells have such a high glycolytic rate?. Med Hypotheses 1990, 32(2):151-155.
4. Warren S. The inmediate cause of death in cancer. Am J Med Sci 1932, 184:610-613.
5. Dewys W.D., Begg C., Lavin P.T., Band P.R., Bennett J.M., Bertino J.R., et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med 1980, 69(4):491-497.
6. Loprinzi C.L., Michalak J.C., Schaid D.J., Mailliard J.A., Athmann L.M., Goldberg R.M., et al. Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia. J Clin Oncol 1993, 11(4):762-767.
7. Bruera E., Macmillan K., Kuehn N., Hanson J., MacDonald R.N. A controlled trial of megestrol acetate on appetite, caloric intake, nutritional status, and other symptoms in patients with advanced cancer. Cancer 1990, 66(6):1279-1282.
8. Neri B., Garosi V.L., Intini C. Effect of medroxyprogesterone acetate on the quality of life of the oncologic patient: a multicentric cooperative study. Anticancer Drugs 1997, 8(5):459-465.
9. McCarthy H.D., Crowder R.E., Dryden S., Williams G. Megestrol acetate stimulates food and water intake in the rat: effects on regional hypothalamic neuropeptide Y concentrations. Eur J Pharmacol 1994, 265(1-2):99-102.
10. Mantovani G., Maccio A., Esu S., Lai P., Santona M.C., Massa E., et al. Medroxyprogesterone acetate reduces the in vitro production of cytokines and serotonin involved in anorexia/cachexia and emesis by peripheral blood mononuclear cells of cancer patients. Eur J Cancer 1997, 33(4):602-607.
11. Berenstein E.G., Ortiz Z. Megestrol acetate for the treatment of anorexia-cachexia syndrome. Cochrane Database Syst Rev 2005, 2:CD004310.
12. Von Roenn J.H., Armstrong D., Kotler D.P., Cohn D.L., Klimas N.G., Tchekmedyian N.S., et al. Megestrol acetate in patients with AIDS-related cachexia. Ann Intern Med 1994, 121(6):393-399.
13. Loprinzi C.L., Schaid D.J., Dose A.M., Burnham N.L., Jensen M.D., et al. Body-composition changes in patients who gain weight while receiving megestrol acetate. J Clin Oncol 1993, 11(1):152-154.
14. Busquets S., Serpe R., Sirisi S., Toledo M., Coutinho J., Martinez R., et al. Megestrol acetate: its impact on muscle protein metabolism supports its use in cancer cachexia. Clin Nutr 2010, 29(6):733-737.
15. Tessitore L., Costelli P., Bonetti G., Baccino F.M. Cancer cachexia, malnutrition, and tissue protein turnover in experimental animals. Arch Biochem Biophys 1993, 306(1):52-58.
16. 14C]triolein. Biochem J 1986, 239(1):233-236.
17. Browning J.D., MacDonald R.S., Thornton W.H., O'Dell B.L., et al. Reduced food intake in zinc deficient rats is normalized by megestrol acetate but not by insulin-like growth factor-I. J Nutr 1998, 128(1):136-142.
18. Beck S.A., Tisdale M.J. Effect of megestrol acetate on weight loss induced by tumour necrosis factor alpha and a cachexia-inducing tumour (MAC16) in NMRI mice. Br J Cancer 1990, 62(3):420-424.
19. Mantovani G., Maccio A., Madeddu C., Gramignano G., Serpe R., Massa E., et al. Randomized phase III clinical trial of five different arms of treatment for patients with cancer cachexia: interim results. Nutrition 2008, 24(4):305-313.
20. Busquets S., Figueras M.T., Fuster G., Almendro V., Moore-Carrasco R., Ametller E., et al. Anticachectic effects of formoterol: a drug for potential treatment of muscle wasting. Cancer Res 2004, 64(18):6725-6731.
21. Garcia-Martinez C., Lopez-Soriano F.J., Argiles J.M. Amino acid uptake in skeletal muscle of rats bearing the Yoshida AH-130 ascites hepatoma. Mol Cell Biochem 1995, 148(1):17-23.
22. Argiles J.M., Lopez-Soriano F.J., Busquets S. Mechanisms to explain wasting of muscle and fat in cancer cachexia. Curr Opin Support Palliat Care 2007, 1(4):293-298.
23. Argiles J.M., Lopez-Soriano J., Almendro V., Busquets S., Lopez-Soriano F.J., et al. Cross-talk between skeletal muscle and adipose tissue: a link with obesity?. Med Res Rev 2005, 25(1):49-65.
24. Costelli P., Llovera M., Garcia-Martinez C., Carbo N., Lopez-Soriano F.J., Argiles J.M. Enhanced leucine oxidation in rats bearing an ascites hepatoma (Yoshida AH-130) and its reversal by clenbuterol. Cancer Lett 1995, 91(1):73-78.